Loading stock data…
CRBU
$2.03+0.09 (+4.64%)
Market ClosedLast close May 11
Caribou Biosciences, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Caribou Biosciences, Inc. in the Healthcare sector is trading at $2.03. The stock is currently 43% below its 52-week high of $3.54, remaining 5.2% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why CRBU maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.03
Potential Upside
5%
Whystock Fair Value$2.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$228.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-121.24%
Volume
Today's trading volume
1.89M
Recent News
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +21.81% and -4.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks
The market has climbed 4.4% in the last 7 days and is up 32% over the past year, with earnings forecasted to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when they have solid financials. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to uncover hidden value in quality companies.
Three Best Genomics Stocks for Your Portfolio in 2026
Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.